TOXICIDAD HEMATOLÓGICA ASOCIADA AL TRATAMIENTO CON SULFONAMIDAS Y PIRIMETAMINA EN PACIENTES VIH POSITIVOS Y TOXOPLASMOSIS CEREBRAL EN UN HOSPITAL DE TERCER NIVEL EN COLOMBIA Hematologic toxicity associated with sulfonamides and pyrimethamine treatment in HIV positive patients with cerebral toxoplasmosis at tertiary-slevel hospital in Colombia

Objective: To determine the frequency of hematologic adverse effects associated with treatment for cerebral toxoplasmosis in HIV / AIDS patients. Design: Retrospective case series. Location: University Hospital Hernando Moncaleano Perdomo (HMP), Neiva, Colombia. Population: Patients with cerebral toxoplasmosis and HIV / AIDS treated at the infection service unit between 2006 and 2009. Poblacion: Pacientes con toxoplasmosis cerebral y VIH/SIDA atendidos en el servicio de infectologia entre 2006-2009. Results: 51 patients were evaluated during the study period. 40 (78%) were men. The average age was 33 years. 25 patients had cerebral toxoplasmosis as the first marker of HIV infection. 60.7% of cases had hematologic toxicity. 42% of patients had anemia before treatment. The peak onset of bone marrow toxicity was the sixth day of the start of treatment schedule. The anti-toxoplasma scheme that was most commonly associated with myelotoxicity was the combination of pyrimethamine/sulfadoxine, trimethoprim-sulfamethoxazole and clindamycin in 48% of cases.